Prosecution Insights
Last updated: November 04, 2026
Application No. 18/032,530

RECOMBINANT CLASSICAL SWINE FEVER VIRUS E2 PROTEIN

Final Rejection §112
Filed
Apr 18, 2023
Priority
Oct 19, 2020 — WO PCT/CN2020/121786 +1 more
Examiner
CHEN, STACY BROWN
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Boehringer Ingelheim Vetmedica (China) Co. Ltd.
OA Round
2 (Final)
66%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
626 granted / 946 resolved
+6.2% vs TC avg
Strong +40% interview lift
Without
With
+40.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
66 currently pending
Career history
995
Total Applications
across all art units

Statute-Specific Performance

§101
5.8%
-34.2% vs TC avg
§103
30.3%
-9.7% vs TC avg
§102
14.4%
-25.6% vs TC avg
§112
32.1%
-7.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 946 resolved cases

Office Action

§112
DETAILED ACTION Applicant’s amendment and remarks filed August 26, 2026 are acknowledged. Claims 1, 3, 4, 6, 9, 13, 14, 19, 21, 24 and new claims 35-39 are under examination with regard to the elected species. The species under examination are: QZ07 (represented by SEQ ID NO: 9 in claim 1), mutation at position 10 and related embodiments, and SEQ ID NO: 74 and 75. SEQ ID NO: 75 represents a mutant QZ07 E2 protein having the mutation Y10A. SEQ ID NO: 74 represents a mutant QZ07 E2 protein having the mutation Y10P. Any prior objection or rejection that is not repeated or addressed below is either moot or withdrawn in view of Applicant’s amendment. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 35-39 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 35-39 are directed to methods of claim 1, however, claim 1 is a product claim. The metes and bounds of the claims cannot be determined until proper claim dependency is provided so that it is clear whether the claims are method dependent on claim 24, for example, or product claims dependent on claim 1. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 3, 4, 6, 9, 14, 19, 21, 24 and 35-39 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. It is apparent that mAb 6B8 is required to practice the claimed invention because it is a necessary limitation for the success of the invention as stated in the claims. As a required element it must be known and readily available to the public or obtainable by a repeatable method set forth in the specification, or otherwise readily available to the public. If it is not so obtainable or available, the enablement requirements of 35 U.S.C. § 112, first paragraph, may be satisfied by a deposit of mAb 6B8. See 37 CFR 1.802. One cannot practice the claimed invention without the mAb 6B8, which is used to determine whether the mutated E2 protein has a mutated 6B8 epitope that is not bound by mAb 6B8. One cannot determine whether the E2 protein has the necessary characteristics without access to mAb 6B8. Therefore, access to mAb 6B8 is required to practice the invention. The specification does not provide a repeatable method for mAb 6B8 without access to the mAb 6B8 and it does not appear to be readily available material. It is noted that Applicant has made a deposit of mAb 6B8 at the CCTCC (accession number C2018120) on June 13, 2018 (see paragraph [0286] of the published application US 20240350610). However, the requirements of 37 CFR 1.801- 37 CFR 1.809 have not yet been met. In Applicant’s remarks filed August 26, 2026, Applicant points out how they have already complied with 37 CFR 1.801- 37 CFR 1.809. In response, Applicant does not appear to have complied with 37 CFR 1.808. Applicant indicates that the deposit was made under the terms of the Budapest Treaty. If that is the case, then then an affidavit or declaration by applicants or someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney of record over his or her signature, stating that the deposit has been made under the terms of the Budapest Treaty and that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent, would satisfy the deposit requirements. See 37 CFR 1.808. The examiner has searched the specification and the contents of the application for these statements. The specification does not appear to have these statements and no affidavit, declaration, or statement on the record containing these statements appear to have been filed. If there is an affidavit or declaration already of record, or if there is a statement by an attorney of record over his or her signature already of record, then please indicate the date that the document(s) were filed and the examiner will check the contents of the file. Conclusion No claim is allowed. Claim 13 is objected to for being dependent on a rejected claim but would otherwise be allowable if rewritten in independent form to recite only the elected species of SEQ ID NO: 74 and 57. SEQ ID NO: 74 and 75 are free of the prior art of record. A sequence having at least 95% sequence identity to SEQ ID NO: 9, and having a mutation at position 10, is free of the prior art of record. (Please note that that does not indicate anything about the patentability of the claims as a whole.) THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Visone, can be reached on 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. /STACY B CHEN/Primary Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

Apr 18, 2023
Application Filed
May 27, 2026
Non-Final Rejection mailed — §112
Aug 26, 2026
Response Filed
Sep 30, 2026
Final Rejection mailed — §112
Oct 07, 2026
Applicant Interview (Telephonic)
Oct 07, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779035
TRANSPLANTED CELL PROTECTION VIA INHIBITION OF POLYMORPHONUCLEAR CELLS
4y 3m to grant Granted Nov 03, 2026
Patent 12760316
IgG VARIANTS FOR INDUCTION OF IMMUNE RESPONSE WITHOUT ADJUVANT
4y 1m to grant Granted Oct 13, 2026
Patent 12751617
LYME RELATED INFECTION INDICATOR
3y 5m to grant Granted Oct 06, 2026
Patent 12699093
BIOSENSOR AND METHOD FOR DETERMINATION OF VIRUSES IN CORONAVIRUS FAMILY
3y 1m to grant Granted Aug 04, 2026
Patent 12653883
ALPHAVIRUS NEOANTIGEN VECTORS AND INTERFERON INHIBITORS
5y 1m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+40.3%)
3y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 946 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month